|
| Study | BCVA | Visual field | Contrast
sensitivity | ERG | Dark adaptometry | Number of adverse events per group (experimental/control) |
|
| Chatzinoff et al. 1968 [28] | No differences | No differences | NA | NA | No differences | NA |
|
| Newsome et al. 1987 [32] | NA | No differences
(Goldman perimetry) | NA | Not recordable in most patients | NA | 3 minor AEs |
|
| Berson et al. 1993 [8] and Sibulesky et al. 1999 [33] | No differences (ETDRS) | No differences
(Goldman perimetry) | NA | Slower rate of decline in vitamin A and vitamin A + E groups, faster decline in vitamin E group (30 Hz ERG) | NA | 4 severe AEs (total), no differences between groups in minor and severe AE |
|
| Vingolo et al. 1998 [6] | NA | NA | NA | Improvement in maximal ERG amplitude recorded with low-noise method in HBO group | NA | NA |
|
| Berson et al. 2004 [27] | No differences (ETDRS) | No differences
(Humphrey visual field analyzer) | NA | No differences (30 Hz ERG) | NA | 1 severe AE in the placebo group |
|
| Berson et al. 2004a [26] | No differences (ETDRS) | Slower decline in no vitamin A prior to entry + DHA group
(Humphrey visual field analyzer) | NA | Slower decline in no vitamin A prior to entry + DHA group (30 Hz ERG) | NA | 1 severe AE in the placebo group |
|
| Hoffman et al. 2004 [30] and Wheaton et al. 2003 [34] | No differences (logMAR) | No differences
(Humphrey visual field analyzer) | NA | No differences (light-adapted cone 31 Hz, rod, or maximal ERG amplitudes) | No differences | Minor AE in 4 patients in DHA and 6 in placebo groups.
No severe AE |
|
| Bahrami et al. 2006 [9] | No differences (ETDRS) | Positive effect on preserving VF
(Goldman perimetry) | No differences | NA | NA | Minor AE, 1/2 |
|
| Merin et al. 2008 [14] | No differences (LogMar) | No differences
(Goldman perimetry) | No differences | NA | NA | No severe AE
Allergic reaction in 3 |
|
| Vingolo et al. 2008 [5] | Slower decline in HBO group (Snellen chart) | Higher percentage of stabilization of Goldmann perimetry-target I4 and HFA 10-2 visual fields in the HBO group versus control group | NA | Statistically significant improvement of ERG b-wave amplitude recorded with low-noise method in HBO group versus controls | NA | NA |
|
| Berson et al. 2010 [10] | No differences (ETDRS) | No differences
(Humphrey visual field analyzer) | NA | No differences | | |
|
| Nakazawa et al. 2011 [13] | NA | Slower progression of central VF in treatment group
(Humphrey visual field analyzer) | NA | NA | NA | No severe AE |
|
| Rotenstreich et al. 2013 [11] | No differences (ETDRS) | No differences in dark- and light-adapted VF
(Goldmann perimetry) | NA | Significant increase of dark- and light-adapted ERG b-wave amplitude in treatment group versus placebo | NA | No AE |
|
| Birch et al. 2013 [15] | No differences (ETDRS) | No differences with low dose; significant worsening in high dose versus sham
(Humphrey visual field analyzer) | NA | No differences (30 Hz flicker and single-flash ERG) | NA | Low dose: 5 ocular AEs
High dose: 37 ocular AEs (26 mioses)
No severe AE |
|
| Hoffman et al. 2014 [29] | NA | NA | NA | No differences (31 Hz flicker ERG) | NA | 22/20 TEAEs
No severe AE |
|
| Hughbanks-Wheaton et al. 2014 [31] | NA | NA | NA | NA | NA | 22/20 TEAEs
No severe AE
1 dropout due to gastrointestinal symptoms |
|
| Kumar et al. 2014 [12] | Significant improvement in treatment group | NA | NA | Significant improvement in treatment group | NA | 3 gastrointestinal symptoms
No severe AE |
|
